



February 27, 2017

Epizyme Announces 2016 Fourth Quarter and Full-Year Results Conference Call Date and March Investor Conferences

CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and webcast at 8:30 a.m. ET on Thursday, March 9, 2017, to discuss its fourth quarter and full-year 2016 financial results and other business highlights.

To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 79789689. The webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.epizyme.com.

March Investor Conferences

In addition, the company will be participating in the following March conferences:

- 1 Cowen and Company 37th Annual Health Care Conference (fireside chat format) on Monday, March 6, 2017 at 4:40 p.m. ET in New York City; and,
- 1 Oppenheimer 27th Annual Healthcare Conference (fireside chat format) on Tuesday, March 21, 2017 at 9:10 a.m. ET in New York City.

Replays of the webcasts of the presentations can be accessed at the investor section of the Company's website at <http://www.epizyme.com>.

About Epizyme, Inc.

Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting cancer treatment through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies as a monotherapy and combination therapy and in relapsed and front-line disease. Using the Company's proprietary platform, Epizyme has pioneered the identification and development of small molecule inhibitors of chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, which can allow cancer cells to grow and proliferate. By focusing on the genetic drivers of cancers, Epizyme's science seeks to match targeted medicines with the specific patients that need it. For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Contacts:

Investors

Monique Allaire, THRUST IR

monique@thrustir.com

(617) 895-9511

Media

Paul Kidwell

paulkidwell@comcast.net

(617) 680-1088

 Primary Logo

Source: Epizyme, Inc.

News Provided by Acquire Media